Prominent publications by Steven I Sherman

KOL Index score: 19239

BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules ...

Also Ranks for: Thyroid Nodules |  management guidelines |  task force |  critical appraisal |  published evidence
KOL Index score: 18764

BACKGROUND: Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer.

METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice ...

Also Ranks for: Patients Sorafenib |  radioactive iodine |  3 trial |  thyroid cancer |  progressionfree survival
KOL Index score: 17065

BACKGROUND: The follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common histotype among papillary thyroid cancers (PTCs). Although the prognosis of FVPTC is similar to the conventional phenotype, differential diagnostic difficulties may not be uncommon with other follicular thyroid neoplasms, and little is known about their genetic alterations. Defining these alterations may lead to the identification of diagnostic and biologic markers.

METHODS: In this study, ...

Also Ranks for: Genetic Alterations |  follicular variant |  papillary thyroid |  signaling pathways |  protein kinase
KOL Index score: 16430

PURPOSE: No effective treatment options currently are available to patients with anaplastic thyroid cancer (ATC), resulting in high mortality rates. Epidermal growth factor (EGF) has been shown to play a role in the pathogenesis of many types of cancer, and its receptor (EGFR) provides an attractive target for molecular therapy.

EXPERIMENTAL DESIGN: The expression of EGFR was determined in ATC in vitro and in vivo and in human tissue arrays of ATC. We assessed the potential of the EGFR ...

Also Ranks for: Growth Factor |  egfr inhibitor gefitinib |  anaplastic thyroid |  atc cells |  molecular therapy
KOL Index score: 16055

BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).

METHODS: In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was ...

Also Ranks for: Patients Placebo |  refractory thyroid |  lenvatinib adverse effects |  progressionfree survival |  hazard ratio
KOL Index score: 15815

BACKGROUND: The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily responsible for the increased overall incidence of thyroid cancer. Sorafenib is a multikinase inhibitor that targets several molecular signals believed to be involved in the pathogenesis of thyroid cancer, including those implicated in DTC. In phase II studies of ...

Also Ranks for: Thyroid Cancer |  sorafenib patients |  radioactive iodine |  phase iii |  efficacy safety
KOL Index score: 14986

BACKGROUND: Cabozantinib significantly prolonged progression-free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P < .001). An exploratory analysis of phase 3 trial data evaluated the influence of rearranged during transfection (RET) and RAS (HRAS, KRAS, and NRAS) mutations on cabozantinib clinical activity.

METHODS: Patients (n = 330) were randomized to cabozantinib (140 mg/day) or a placebo. The primary endpoint was PFS. ...

Also Ranks for: Ras Mutations |  ret mutation |  thyroid cancer |  cabozantinib placebo |  patients mtc
KOL Index score: 14499

Lenvatinib significantly prolonged progression-free survival (PFS) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial. This subanalysis evaluated the efficacy and safety of lenvatinib in Japanese patients who participated in SELECT. Outcomes for Japanese patients (lenvatinib, n = 30; placebo, n = 10) were assessed in relationship to the SELECT ...

Also Ranks for: Japanese Patients |  3 study |  thyroid cancer |  lenvatinib placebo |  refractory differentiated
KOL Index score: 14459

BACKGROUND: Hürthle cell neoplasms, often considered a variant of follicular thyroid neoplasms, represent 3% of thyroid carcinomas. Only a handful of publications have focused on the biologic behavior, prognostic factors, and treatment outcomes of Hürthle cell carcinoma. The objective of the current study was to identify the clinical and pathologic features of Hürthle cell carcinomas that predict disease progression or death.

METHODS: The authors reviewed medical records of patients who ...

Also Ranks for: Hürthle Cell Neoplasms |  patients hcc |  radioactive iodine |  distant metastases |  extensive surgery
KOL Index score: 13394

PURPOSE: Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins.

PATIENTS AND METHODS: We treated 35 patients with differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in a phase I trial. Sorafenib and ...

Also Ranks for: Differentiated Thyroid |  kinase inhibitor |  stable disease |  6 months |  dtc mtc
KOL Index score: 13018

BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association's guidelines for the management of these disorders was published in 2006, a large amount of new information has become available, prompting a revision of the guidelines.

METHODS: Relevant articles through December 2008 were reviewed by the task force and categorized by topic and level of evidence ...

Also Ranks for: Thyroid Nodules |  management guidelines |  patients disorders |  task force |  suppression therapy
KOL Index score: 12958

BACKGROUND: About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer.

METHODS: We did an open-label, non-randomised, phase 2 trial at ...

Also Ranks for: Papillary Thyroid |  vemurafenib patients |  radioactive iodine |  tumor carcinoma |  phase 2
KOL Index score: 12819

PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article.

PATIENTS AND METHODS: A phase I dose-escalation study of oral ...

Also Ranks for: Patients Mtc |  medullary thyroid cancer |  clinical benefit |  oral tyrosine |  6 months

Key People For Thyroid Cancer

Top KOLs in the world
Martin **** ************
thyroid cancer adrenocortical carcinoma radioactive iodine
Steven * *******
thyroid cancer radioactive iodine anaplastic carcinoma
Furio ******
thyroid cancer serum tg multiple endocrine
Robert ******* ******
thyroid cancer active surveillance risk stratification
Bryan * ******
thyroid cancer cell lines telomerase activity
Yuri * *********
thyroid cancer ret ptc ras mutations

Steven I Sherman:Expert Impact

Concepts for whichSteven I Shermanhas direct influence:Thyroid cancer,  Thyroid carcinoma,  Differentiated thyroid cancer,  Thyroid nodules,  Differentiated thyroid,  Papillary thyroid,  Medullary thyroid,  Medullary thyroid cancer.

Steven I Sherman:KOL impact

Concepts related to the work of other authors for whichfor which Steven I Sherman has influence:Thyroid cancer,  Lymph node,  Radioactive iodine,  Carcinoma papillary,  Active surveillance,  Tumor size,  Braf mutation.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

The University of Texas MD Anderson Cancer Center, Houston, TX, USA | Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX; | The University of Texas MD Anderson Cancer Center, Houston,